ClinicalTrials.gg
CompletedNCT01901432Updated Jul 30, 2019Results posted

A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera

A Phase 1/2 interventional study of Givinostat in Polycythemia Vera, sponsored by Italfarmaco. Completed at 25 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-30.

Sponsored by Italfarmaco · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies in Polycythemia Vera with a site in Italy — 8 open to participants now, 15 under way, 3 of them phase 3. Polycythemia Vera · Italy.

Enrollment
26th of 31
48 · median 127
Started
2013
with 5 others
Phase 1/2
3 of 44
none open now
Registered
20th of 44
by date
Lead sponsor
5 of 44
Italfarmaco

Among the 44 studies in Polycythemia Vera with a site in Italy, this one is the 26th largest by enrollment of the 31 interventional ones that give a count, is one of 6 that started in 2013, is one of 3 in phase 1/2, and was the 20th registered.

Polycythemia Vera

278 studies on the registry are indexed under Polycythemia Vera; 53 are open to participants now.

Browse Polycythemia Vera studies →

Open to participants now

8 of the 44 studies in Polycythemia Vera with a site in Italy are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 42 Polycythemia Vera studies recruiting now, 38 (90%) set no upper age limit and 1 (2%) stops at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Polycythemia Vera with a site in Italy, or all of them as a file.
02

Study summary

This is a two-part, multicenter, open label, non-randomized, phase Ib/II study to assess the safety and tolerability, Maximum Tolerated Dose and preliminary efficacy of Givinostat in patients with JAK2V617F positive Polycythemia Vera. Part A is the dose finding part while Part B is assessing the preliminary efficacy. Patients will be enrolled either in Part A or Part B and transition from one part to the other is not allowed.

Eligible patients for this study will have a confirmed diagnosis of Polycythemia Vera according to the revised World Health Organization criteria. Only if the enrolment in Part A is slow (i.e. \< 5 patients enrolled in 3 months), eligibility for this part of the study may be expanded to all patients with chronic myeloproliferative neoplasms.

Study therapy will be administered in 28 day cycles (4 weeks of treatment). Disease response will be evaluated according to the European LeukemiaNet criteria after 3 and 6 cycles (i.e. at weeks 12 and 24, respectively) of treatment with Givinostat for both parts of the study. All phlebotomies performed in the first 3 weeks of treatment will not be counted to assess the clinico-haematological response.

The study will last up to a maximum of 24 weeks of treatment. However, after completion of the trial, all patients achieving clinical benefit will be allowed to continue treatment with Givinostat (at the same dose and schedule) in a long-term study.

Safety will be monitored at each visit throughout the entire duration of the study. Treatment will be administered on an outpatient basis and patients will be followed regularly with physical and laboratory tests, as specified in the protocol; in case of hospitalization, the treatment will be continued or interrupted according to the Investigators' decision.

Read the detailed description

This is a two-part, multicenter, open label, non-randomized, phase Ib/II study to assess the safety and tolerability, MTD and preliminary efficacy of Givinostat in patients with JAK2V617F positive PV.

Part A is the dose escalation portion of the study and, once the MTD has been established, Part B will commence where the preliminary efficacy of Givinostat in PV patients will be established. Patients will be enrolled either in Part A or Part B and transition from one part to the other is not allowed. Only PV patients from Part A assigned to the dose selected for Part B (MTD) may be counted towards the efficacy assessment in Part B.

Eligible patients for this study will have a confirmed diagnosis of PV according to the revised WHO criteria and the JAK2V617F positivity. Only if the enrolment in Part A is slow (i.e. \< 5 patients enrolled in 3 months), eligibility for this part of the study may be expanded to all patients with cMPN.

After providing informed written consent before undertaking any protocol-related procedure, a unique patient identification code (i.e. patient screening ID which will be a combination of his/her site ID, study part ID and patient screening number, e.g. IT01-A01) will be assigned to each patient and it will identify the patient within his/her enrolment confirmation by Italfarmaco S.p.A. or its designee and never be reused in case of screening failure. After the enrolment confirmation and the assignation of the dose level before the first drug intake, a unique patient identification code (i.e. patient ID which will be a combination of patient screening number ID and dose level ID, e.g. IT01-A01-DL1) will be assigned to each patient and it will identify the patient throughout his/her participation in the study and never be reused in case of premature drop-out.

Study therapy will be administered in 28 day cycles. In fact, the "cycle" is defined as 4 weeks of treatment.

Disease response will be evaluated according to the clinico-haematological ELN criteria after 3 and 6 cycles (i.e. at weeks 12 and 24, respectively) of treatment with Givinostat for both parts of the study. All phlebotomies performed in the first 3 weeks of treatment will not be counted to assess the clinico-haematological response.

The study will last up to a maximum of 24 weeks of treatment. However, after completion of the trial, all patients achieving clinical benefit will be allowed to continue treatment with Givinostat (at the same dose and schedule) in a long-term study (Study N.: DSC/11/2357/44).

Safety will be monitored at each visit throughout the entire duration of the study. Treatment will be administered on an outpatient basis and patients will be followed regularly with physical and laboratory tests, as specified in the protocol; in case of hospitalization, the treatment will be continued or interrupted according to the Investigators' decision.

03

Conditions studied

  • Polycythemia Vera

Keywords

  • chronic myeloproliferative neoplasms
  • Polycythemia Vera
  • Essential Thrombocythemia
  • Primary Myelofibrosis
  • Post-Polycythemia Vera Myelofibrosis
  • Post-Essential Thrombocythemia Myelofibrosis
  • Givinostat
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must be able to provide and be willing to sign an informed consent form;
  2. Patients must have an age ≥18 years;
  3. Patients must have a confirmed diagnosis of Polycythemia Vera according to the revised World Health Organization criteria;
  4. Patients must have mutated Janus Kinase 2 (mutation V617F) positive disease;
  5. Patients must have an active/not controlled disease defined as

    1. hematocrit ≥ 45% or hematocrit \<45% in need of phlebotomy, and
    2. count > 400 x109/L, and
    3. white blood cell count > 10 x109/L;
  6. Patients must have an (ECOG) performance status ≤ 1 in Part A, ECOG performance status ≤ 2 in Part B within 7 days of initiating study drug;
  7. Female patient of has a negative serum or urine pregnancy test within 72 hours of the first dose of study therapy;
  8. Use of an effective means of for women of childbearing potential and men with partners of childbearing potential;
  9. Adequate and acceptable organ function within 7 days of initiating study drug;
  10. Willingness and capability to comply with the requirements of the study.

Note that if the enrolment in Part A is slow (i.e. \< 5 patients enrolled in 3 months), eligibility for this part of the study may be expanded to all patients with chronic myeloproliferative neoplasms. In this case, the inclusion criteria 5 will be modified as following only for Part A:

  1. Patients must have an active/not controlled disease defined as:
  1. Essential Thrombocythemia patients: Platelet count > 600 x109/L;
  2. Myelofibrosis patients: no response according to European Myelofibrosis Network criteria.

Exclusion criteria

Exclusion Criteria:

  1. Active bacterial or mycotic infection requiring antimicrobial treatment;
  2. Pregnancy or nursing;
  3. A interval prolongation at baseline;
  4. Use of concomitant medications known to prolong the corrected QT interval;
  5. Clinically significant cardiovascular disease including:

    1. Uncontrolled hypertension despite medical treatment, myocardial infarction, unstable angina within 6 months from study start;
    2. Grade II or greater congestive heart failure;
    3. History of any cardiac arrhythmia requiring medication (irrespective of its severity);
    4. A history of additional risk factors for torsade de pointes;
  6. Known positivity for human immunodeficiency;
  7. Known active virus and/or virus infection;
  8. count \< 100 x109/L within 14 days before enrolment;
  9. \< 1.2x109/L within 14 days before enrolment;
  10. Serum creatinine > 2 times the ;
  11. Total serum > 1.5 times the upper limit of normal except in case of Gilbert's disease;
  12. Serum /alanine aminotransferase (AST/ALT) > 3 times the upper limit of normal;
  13. History of other diseases (including active tumours), metabolic dysfunctions, physical examination findings, or clinical laboratory findings giving reasonable suspicion of a disease or condition that contraindicates use of an drug or that might affect interpretation of the results of the study or render the subject at high risk from treatment complications;
  14. Prior treatment with a Janus Kinase 2 or Histone Deacetylase inhibitor or participation in an interventional clinical trial for chronic myeloproliferative neoplasms;
  15. Systemic treatment for chronic myeloproliferative neoplasms other than aspirin/cardio aspirin;
  16. Hydroxyurea within 28 days before enrolment;
  17. Interferon alpha within 14 days before enrolment;
  18. Anagrelide within 7 days before enrolment;
  19. Any other investigational drug or device within 28 days before enrolment;
  20. Patient with known to the components of study therapy.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Givinostat

    In Part A patients will treated in dose levels at the following daily doses of Givinostat: * 50 mg b.i.d., * 100 mg b.i.d.; * 150 mg b.i.d., * 200 mg b.i.d.; * 150 mg t.i.d.; * 200 mg t.i.d.. Intermediate dose levels and, consequently, additionally dose levels may be used to establish the Maximum Tolerated Dose. In Part B patients will be treated at the Maximum Tolerated Dose established in Part A. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each.

    Drug: Givinostat

Interventions

  • In Part A patients will treated in dose levels at the following daily doses of Givinostat: * 50 mg b.i.d., * 100 mg b.i.d.; * 150 mg b.i.d., * 200 mg b.i.d.; * 150 mg t.i.d.; * 200 mg t.i.d.. Intermediate dose levels and, consequently, additionally dose levels may be used to establish the Maximum Tolerated Dose. In Part B patients will be treated at the Maximum Tolerated Dose established in Part A. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each.

    Also known as: Givinostat (ITF2357)

06

What researchers measure

Primary outcomes

  1. Number of Patients Experiencing Treatment-emergent Adverse Events (TEAEs) in Part A of the Study

    Evaluations were performed on the type, incidence and severity of TEAEs, graded according to Common Terminology Criteria for Adverse Events (CTCAE) v. 4.03, following administration of givinostat for up to 6 cycles of treatment in Part A. Grades 1 through 5 were as follows: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life threatening or requiring hospitalisation; Grade 4: Life threatening consequences; Grade 5: Death related to AE. Results are reported as number of patients with TEAEs for each of the indicated categories. Definitions: drug-related TEAE / treatment-emergent serious adverse event (TESAE) corresponded to reasonable suspicion that the TEAE / TESAE was associated with the use of the study drug, according to investigator assessment; discontinuation refers to discontinuation from treatment.

    Time frame: 168 days (up to Cycle 6 Day 28 in Part A).

  2. Number of Dose Limiting Toxicities (DLTs) After 1 Cycle in Part A of the Study

    The MTD of givinostat was based only on Cycle 1 DLTs. A DLT was defined as the following drug-related toxicity: * Grade 4 hematological toxicity, or * Grade 3 febrile neutropenia, or * Grade ≥3 non-hematological toxicity (with the exception Grade 3 diarrhea without adequate supportive care lasting less than 3 days, and Grade 3 nausea or vomiting without adequate supportive care lasting less than 3 days), or * Any drug-related serious AE, or * Any toxicity clearly not related to disease progression or intercurrent illness requiring interruption of dosing for more than 3 days during first cycle. At end of Cycle 1, for the third patient in each DL, the safety of the 3 patients treated for 1 cycle was reviewed and it was decided if the dose should be escalated or not. Results are reported as the number of patients with DLT events for Cycle 1 in Part A.

    Time frame: 28 days (up to Cycle 1 Day 28 in Part A).

  3. Number of Patients Experiencing TEAEs After 3 Cycles in Part B of the Study

    Evaluations were performed on the type, incidence and severity of TEAEs, graded according to CTCAE v. 4.03, following administration of givinostat at the MTD for up to 3 cycles of treatment in Part B. Grades 1 through 5 were as follows: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life threatening or requiring hospitalisation; Grade 4: Life threatening consequences; Grade 5: Death related to AE. Results are reported as number of patients with TEAEs for each of the indicated categories. Definitions: drug-related TEAE / TESAE corresponded to reasonable suspicion that the TEAE / TESAE was associated with the use of the study drug, according to investigator assessment; discontinuation refers to discontinuation from treatment.

    Time frame: 84 days (up to Cycle 3 Day 28 in Part B).

  4. Overall Response Rate (ORR) (i.e. Complete Response [CR] and Partial Response [PR]) After 3 Cycles in Part B of the Study

    ORR, CR and PR following administration of givinostat at MTD for 3 cycles in Part B, reported as percentage of patients with a response. Response was evaluated according to the clinico-hematological European LeukemiaNet (ELN) response criteria. If Investigator's clinical response assessment (taking into account the overall medical judgment of the specific patient's case) was not in agreement with exact application of the ELN response criteria, the Investigator's assessment superseded the mathematical application of these criteria and was used for analysis. CR defined as: 1. Hematocrit (HCT) \<45% without phlebotomy, and 2. Platelets ≤400 x10\^9/litre (L), and 3. White Blood Cell count ≤10 x10\^9/L, and 4. Normal spleen size, and 5. No disease-related systemic symptoms (i.e. pruritus, headache, microvascular disturbances). PR defined as: Patients not fulfilling CR and 1. HCT \<45% without phlebotomy, or 2. Response in ≥3 other criteria.

    Time frame: 84 days (up to cycle 3 Day 28 in Part B).

Secondary outcomes

  1. ORR After 3 Cycles and After 6 Cycles in Part A of the Study

    ORR following administration of givinostat after 3 cycles and after 6 cycles in Part A, reported as percentage of patients with a response. Response was evaluated according to the clinico-hematological ELN response criteria. If Investigator's clinical response assessment (taking into account the overall medical judgment of the specific patient's case) was not in agreement with exact application of the ELN response criteria, the Investigator's assessment superseded the mathematical application of these criteria and was used for analysis. Analysis performed using the dataset for all Part A patients combined.

    Time frame: 84 and 168 days (up to Cycle 3 Day 28 and Cycle 6 Day 28 in Part A).

  2. ORR After 6 Cycles in Part B of the Study

    ORR following administration of givinostat at the MTD for 6 cycles in Part B, reported as percentage of patients with a response. Response was evaluated according to the clinico-hematological ELN response criteria. If Investigator's clinical response assessment (taking into account the overall medical judgment of the specific patient's case) was not in agreement with exact application of the ELN response criteria, the Investigator's assessment superseded the mathematical application of these criteria and was used for analysis.

    Time frame: 168 days (up to Cycle 6 Day 28 in Part B).

  3. Number of Patients Experiencing TEAEs After 6 Cycles in Part B of the Study

    Evaluations were performed on the type, incidence and severity of TEAEs, graded according to CTCAE v. 4.03, following administration of givinostat at the MTD for up to 6 cycles of treatment in Part B. Grades 1 through 5 were as follows: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life threatening or requiring hospitalisation; Grade 4: Life threatening consequences; Grade 5: Death related to AE. Results are reported as number of patients with TEAEs for each of the indicated categories. Definitions: drug-related TEAE / TESAE corresponded to reasonable suspicion that the TEAE / TESAE was associated with the use of the study drug, according to investigator assessment; discontinuation refers to discontinuation from treatment. Results are reported as number of patients with TEAEs for each of the indicated categories.

    Time frame: 168 days (up to Cycle 6 Day 28 in Part B).

  4. Assessment of Maximum Plasma Concentration (Cmax) of Givinostat and Metabolites (ITF2374 and ITF2375) in Part A of the Study

    Pharmacokinetic (PK) evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Cmax following administration of givinostat for 1 cycle in Part A. PK calculations were performed by standard non-compartmental analysis. Results are reported for Cycle 1 Day 1 and Cycle 1 Day 28. Note: concentration data for ITF2374 (Cycle 1 Day 1 and Cycle 1 Day 28) and for ITF2375 (Cycle 1 Day 1) in the DL0 dose group of Part A were not available for PK analysis.

    Time frame: Blood samples were collected in Part A on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 1 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.

  5. Assessment of Time to Maximum Plasma Concentration (Tmax) of Givinostat and Metabolites (ITF2374 and ITF2375) in Part A of the Study

    PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Tmax following administration of givinostat for 1 cycle in Part A. PK calculations were performed by standard non-compartmental analysis. Results are reported for Cycle 1 Day 1 and Cycle 1 Day 28. Note: concentration data for ITF2374 (Cycle 1 Day 1 and Cycle 1 Day 28) and for ITF2375 (Cycle 1 Day 1) in the DL0 dose group of Part A were not available for PK analysis.

    Time frame: Blood samples were collected in Part A on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 1 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.

  6. Assessment of Time of the Last Detectable Concentration (Tlast) of Givinostat and Metabolites (ITF2374 and ITF2375) in Part A of the Study

    PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Tlast following administration of givinostat for 1 cycle in Part A. PK calculations were performed by standard non-compartmental analysis. Results are reported for Cycle 1 Day 1 and Cycle 1 Day 28. Note: concentration data for ITF2374 (Cycle 1 Day 1 and Cycle 1 Day 28) and for ITF2375 (Cycle 1 Day 1) in the DL0 dose group of Part A were not available for PK analysis.

    Time frame: Blood samples were collected in Part A on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 1 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.

  7. Assessment of Area Under Plasma Concentration Versus the Time Curve up to the Last Detectable Concentration (AUClast) of Givinostat and Metabolites (ITF2374 and ITF2375) in Part A of the Study

    PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of AUClast following administration of givinostat for 1 cycle in Part A. PK calculations were performed by standard non-compartmental analysis and AUClast was calculated using the linear trapezoidal rule. Results are reported for Cycle 1 Day 1 and Cycle 1 Day 28. Note: concentration data for ITF2374 (Cycle 1 Day 1 and Cycle 1 Day 28) and for ITF2375 (Cycle 1 Day 1) in the DL0 dose group of Part A were not available for PK analysis.

    Time frame: Blood samples were collected in Part A on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 1 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.

  8. Assessment of Area Under Plasma Concentration Versus the Time Curve in the Dosing Interval (0-12 Hours) (AUC0-12) of Givinostat and Metabolites (ITF2374 and ITF2375) in Part A of the Study

    PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of AUC0-12 following administration of givinostat for 1 cycle in Part A. PK calculations were performed by standard non-compartmental analysis and AUC0-12 was calculated using the linear trapezoidal rule. Results are reported for Cycle 1 Day 1 and Cycle 1 Day 28. Note:concentration data for ITF2374 (Cycle 1 Day 1 and Cycle 1 Day 28) across all dose groups and for ITF2375 (Cycle 1 Day 1) in the DL0 dose group of Part A were not available for PK analysis.

    Time frame: Blood samples were collected in Part A on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 1 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.

  9. Assessment of Cmax of Givinostat and Metabolites (ITF2374 and ITF2375) in Part B of the Study

    PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Cmax following administration of givinostat for 2 cycles in Part B. PK calculations were performed by standard non-compartmental analysis. Following definition of the MTD in Part A, during Part B Cycle 1, givinostat was administered at 100 mg b.i.d. and during Part B Cycle 2 was administered at 100 mg, 75 mg and 50 mg b.i.d. (since dose reductions due to TEAEs were allowed from Cycle 2 onwards, as per protocol). Results are reported for Cycle 1 Day 1 and Cycle 2 Day 28 for the doses administered during Part B. Note: PK evaluation for the givinostat 75 mg and 50 mg b.i.d. dose groups for Cycle 1 Day 1 was not applicable (since all received givinostat 100 mg b.i.d.). Additionally, concentration data for ITF2375 (Cycle 1 Day 28) in the 50 mg b.i.d. dose group was not available for PK analysis.

    Time frame: Blood samples were collected in Part B on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 2 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.

  10. Assessment of Tmax of Givinostat and Metabolites (ITF2374 and ITF2375) in Part B of the Study

    PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Tmax following administration of givinostat for 2 cycles in Part B. PK calculations were performed by standard non-compartmental analysis. Following definition of the MTD in Part A, during Part B Cycle 1, givinostat was administered at 100 mg b.i.d. and during Part B Cycle 2 was administered at 100 mg, 75 mg and 50 mg b.i.d. (since dose reductions due to TEAEs were allowed from Cycle 2 onwards, as per protocol). Results are reported for Cycle 1 Day 1 and Cycle 2 Day 28 for the doses administered during Part B. Note: PK evaluation for the givinostat 75 mg and 50 mg b.i.d. dose groups for Cycle 1 Day 1 was not applicable (since all received givinostat 100 mg b.i.d.). Additionally, concentration data for ITF2375 (Cycle 1 Day 28) in the 50 mg b.i.d. dose group was not available for PK analysis.

    Time frame: Blood samples were collected in Part B on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 2 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.

  11. Assessment of Tlast of Givinostat and Metabolites (ITF2374 and ITF2375) in Part B of the Study

    PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Tlast following administration of givinostat for 2 cycles in Part B. PK calculations were performed by standard non-compartmental analysis. Following definition of the MTD in Part A, during Part B Cycle 1, givinostat was administered at 100 mg b.i.d. and during Part B Cycle 2 was administered at 100 mg, 75 mg and 50 mg b.i.d. (since dose reductions due to TEAEs were allowed from Cycle 2 onwards, as per protocol). Results are reported for Cycle 1 Day 1 and Cycle 2 Day 28 for the doses administered during Part B. Note: PK evaluation for the givinostat 75 mg and 50 mg b.i.d. dose groups for Cycle 1 Day 1 was not applicable (since all received givinostat 100 mg b.i.d.). Additionally, concentration data for ITF2375 (Cycle 1 Day 28) in the 50 mg b.i.d. dose group was not available for PK analysis.

    Time frame: Blood samples were collected in Part B on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 2 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.

  12. Assessment of AUClast of Givinostat and Metabolites (ITF2374 and ITF2375) in Part B of the Study

    PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of AUClast following administration of givinostat for 2 cycles in Part B. PK calculations were performed by standard non-compartmental analysis and AUClast was calculated using the linear trapezoidal rule. Following definition of the MTD in Part A, during Part B Cycle 1, givinostat was administered at 100 mg b.i.d. and during Part B Cycle 2 was administered at 100 mg, 75 mg and 50 mg b.i.d. (since dose reductions due to TEAEs were allowed from Cycle 2 onwards, as per protocol). Results are reported for Cycle 1 Day 1 and Cycle 2 Day 28 for the for the doses administered during Part B. Note: PK evaluation for the givinostat 75 mg and 50 mg b.i.d. dose groups for Cycle 1 Day 1 was not applicable (since all received givinostat 100 mg b.i.d.). Additionally, concentration data for ITF2375 (Cycle 1 Day 28) in the 50 mg b.i.d. dose group was not available for PK analysis.

    Time frame: Blood samples were collected in Part B on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 2 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.

  13. Assessment of AUC0-12 of Givinostat and Metabolites (ITF2374 and ITF2375) in Part B of the Study

    PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of AUC0-12 following administration of givinostat for 2 cycles in Part B. PK calculations were performed by standard non-compartmental analysis and AUClast was calculated using the linear trapezoidal rule. Following definition of the MTD in Part A, during Part B Cycle 1, givinostat was administered at 100 mg b.i.d. and during Part B Cycle 2 was administered at 100 mg, 75 mg and 50 mg b.i.d. (since dose reductions due to TEAEs were allowed from Cycle 2 onwards, as per protocol). Results are reported for Cycle 1 Day 1 and Cycle 2 Day 28 for the doses administered during Part B. Note: PK evaluation for the givinostat 75 mg and 50 mg b.i.d. dose groups for Cycle 1 Day 1 was not applicable (since all received givinostat 100 mg b.i.d.). Additionally, concentration data for ITF2374 (Cycle 1 Day 28) across all dose groups and for ITF2375 in the 50 mg b.i.d. dose group was not available for PK analysis.

    Time frame: Blood samples were collected in Part B on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 2 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.

07

Results

Posted Jun 20, 2019

Participant flow

This was a 2-part, multisite, open-label, non-randomized study to assess givinostat in patients with JAK2\^V617F positive Polycythemia Vera. Part A assessed safety and was the dose escalation portion of study, while Part B assessed preliminary efficacy. Patients were enrolled in 5 countries (France, Germany, Italy, Poland and the United Kingdom).

Participant flow — Overall Study
MilestoneGivinostat DL0 (50 mg b.i.d.) (Part A)Givinostat DL1 (100 mg b.i.d.) (Part A)Givinostat DL1 Expanded (100 mg b.i.d.) (Part A)Givinostat DL6 (100 mg + 50 mg) (Part A)Givinostat at MTD (100 mg b.i.d.) (Part B)
Started333336
Received study drug333335
Completed321327
Not completed01209
Withdrew: Adverse event01101
Withdrew: Withdrawal by subject00105
Withdrew: Physician decision00002
Withdrew: Patient decision to stop study drug00001

Outcome measures

PrimaryNumber of Patients Experiencing Treatment-emergent Adverse Events (TEAEs) in Part A of the Study

Evaluations were performed on the type, incidence and severity of TEAEs, graded according to Common Terminology Criteria for Adverse Events (CTCAE) v. 4.03, following administration of givinostat for up to 6 cycles of treatment in Part A. Grades 1 through 5 were as follows: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life threatening or requiring hospitalisation; Grade 4: Life threatening consequences; Grade 5: Death related to AE. Results are reported as number of patients with TEAEs for each of the indicated categories. Definitions: drug-related TEAE / treatment-emergent serious adverse event (TESAE) corresponded to reasonable suspicion that the TEAE / TESAE was associated with the use of the study drug, according to investigator assessment; discontinuation refers to discontinuation from treatment.

Time frame:
168 days (up to Cycle 6 Day 28 in Part A).
Reported as:
Count of participants · Participants
Number of Patients Experiencing Treatment-emergent Adverse Events (TEAEs) in Part A of the Study
ParticipantsGivinostat DL0 (50 mg b.i.d.) (Part A)Givinostat DL1 (100 mg b.i.d.) (Part A)Givinostat DL1 Expanded (100 mg b.i.d.) (Part A)Givinostat DL6 (100 mg + 50 mg) (Part A)
TEAE3333
Drug-related TEAE1331
TESAE0101
Drug-related TESAE0000
Death due to any cause0000
Grade 3 TEAE0211
Grade 3 drug-related TEAE0210
Grade 4 TEAE0010
Grade 4 drug-related TEAE0010
Grade 5 TEAE0000
Discontinuation due to TEAE0110
Discontinuation due to drug-related TEAE0110
Discontinuation due to TESAE0000
Discontinuation due to drug-related TESAE0000
PrimaryNumber of Dose Limiting Toxicities (DLTs) After 1 Cycle in Part A of the Study

The MTD of givinostat was based only on Cycle 1 DLTs. A DLT was defined as the following drug-related toxicity: * Grade 4 hematological toxicity, or * Grade 3 febrile neutropenia, or * Grade ≥3 non-hematological toxicity (with the exception Grade 3 diarrhea without adequate supportive care lasting less than 3 days, and Grade 3 nausea or vomiting without adequate supportive care lasting less than 3 days), or * Any drug-related serious AE, or * Any toxicity clearly not related to disease progression or intercurrent illness requiring interruption of dosing for more than 3 days during first cycle. At end of Cycle 1, for the third patient in each DL, the safety of the 3 patients treated for 1 cycle was reviewed and it was decided if the dose should be escalated or not. Results are reported as the number of patients with DLT events for Cycle 1 in Part A.

Time frame:
28 days (up to Cycle 1 Day 28 in Part A).
Reported as:
Number · participants
Number of Dose Limiting Toxicities (DLTs) After 1 Cycle in Part A of the Study
participantsGivinostat DL0 (50 mg b.i.d.) (Part A)Givinostat DL1 (100 mg b.i.d.) (Part A)Givinostat DL1 Expanded (100 mg b.i.d.) (Part A)Givinostat DL6 (100 mg + 50 mg) (Part A)
Number of Dose Limiting Toxicities (DLTs) After 1 Cycle in Part A of the Study0100
PrimaryNumber of Patients Experiencing TEAEs After 3 Cycles in Part B of the Study

Evaluations were performed on the type, incidence and severity of TEAEs, graded according to CTCAE v. 4.03, following administration of givinostat at the MTD for up to 3 cycles of treatment in Part B. Grades 1 through 5 were as follows: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life threatening or requiring hospitalisation; Grade 4: Life threatening consequences; Grade 5: Death related to AE. Results are reported as number of patients with TEAEs for each of the indicated categories. Definitions: drug-related TEAE / TESAE corresponded to reasonable suspicion that the TEAE / TESAE was associated with the use of the study drug, according to investigator assessment; discontinuation refers to discontinuation from treatment.

Time frame:
84 days (up to Cycle 3 Day 28 in Part B).
Reported as:
Count of participants · Participants
Number of Patients Experiencing TEAEs After 3 Cycles in Part B of the Study
ParticipantsGivinostat at MTD (100 mg b.i.d.) (Part B)
TEAE35
Drug-related TEAE33
TESAE2
Drug-related TESAE1
Death due to any cause0
Grade 3 TEAE10
Grade 3 drug-related TEAE7
Grade 4 TEAE0
Grade 4 drug-related TEAE0
Grade 5 TEAE0
Discontinuation due to TEAE2
Discontinuation due to drug-related TEAE2
Discontinuation due to TESAE0
Discontinuation due to drug-related TESAE0
PrimaryOverall Response Rate (ORR) (i.e. Complete Response [CR] and Partial Response [PR]) After 3 Cycles in Part B of the Study

ORR, CR and PR following administration of givinostat at MTD for 3 cycles in Part B, reported as percentage of patients with a response. Response was evaluated according to the clinico-hematological European LeukemiaNet (ELN) response criteria. If Investigator's clinical response assessment (taking into account the overall medical judgment of the specific patient's case) was not in agreement with exact application of the ELN response criteria, the Investigator's assessment superseded the mathematical application of these criteria and was used for analysis. CR defined as: 1. Hematocrit (HCT) \<45% without phlebotomy, and 2. Platelets ≤400 x10\^9/litre (L), and 3. White Blood Cell count ≤10 x10\^9/L, and 4. Normal spleen size, and 5. No disease-related systemic symptoms (i.e. pruritus, headache, microvascular disturbances). PR defined as: Patients not fulfilling CR and 1. HCT \<45% without phlebotomy, or 2. Response in ≥3 other criteria.

Time frame:
84 days (up to cycle 3 Day 28 in Part B).
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) (i.e. Complete Response [CR] and Partial Response [PR]) After 3 Cycles in Part B of the Study
percentage of participantsGivinostat at MTD (100 mg b.i.d.) (Part B)
ORR (CR + PR)80.6 (62.53 to 92.55)
CR9.7 (2.04 to 25.75)
PR71.0 (51.96 to 85.78)
SecondaryORR After 3 Cycles and After 6 Cycles in Part A of the Study

ORR following administration of givinostat after 3 cycles and after 6 cycles in Part A, reported as percentage of patients with a response. Response was evaluated according to the clinico-hematological ELN response criteria. If Investigator's clinical response assessment (taking into account the overall medical judgment of the specific patient's case) was not in agreement with exact application of the ELN response criteria, the Investigator's assessment superseded the mathematical application of these criteria and was used for analysis. Analysis performed using the dataset for all Part A patients combined.

Time frame:
84 and 168 days (up to Cycle 3 Day 28 and Cycle 6 Day 28 in Part A).
Reported as:
Number · percentage of participants
ORR After 3 Cycles and After 6 Cycles in Part A of the Study
percentage of participantsGivinostat Total (Part A)
Cycle 3 Day 2872.7 (39.03 to 93.98)
Cycle 6 Day 2872.7 (39.03 to 93.98)
SecondaryORR After 6 Cycles in Part B of the Study

ORR following administration of givinostat at the MTD for 6 cycles in Part B, reported as percentage of patients with a response. Response was evaluated according to the clinico-hematological ELN response criteria. If Investigator's clinical response assessment (taking into account the overall medical judgment of the specific patient's case) was not in agreement with exact application of the ELN response criteria, the Investigator's assessment superseded the mathematical application of these criteria and was used for analysis.

Time frame:
168 days (up to Cycle 6 Day 28 in Part B).
Reported as:
Number · percentage of participants
ORR After 6 Cycles in Part B of the Study
percentage of participantsGivinostat at MTD (100 mg b.i.d.) (Part B)
ORR After 6 Cycles in Part B of the Study80.6 (62.53 to 92.55)
SecondaryNumber of Patients Experiencing TEAEs After 6 Cycles in Part B of the Study

Evaluations were performed on the type, incidence and severity of TEAEs, graded according to CTCAE v. 4.03, following administration of givinostat at the MTD for up to 6 cycles of treatment in Part B. Grades 1 through 5 were as follows: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life threatening or requiring hospitalisation; Grade 4: Life threatening consequences; Grade 5: Death related to AE. Results are reported as number of patients with TEAEs for each of the indicated categories. Definitions: drug-related TEAE / TESAE corresponded to reasonable suspicion that the TEAE / TESAE was associated with the use of the study drug, according to investigator assessment; discontinuation refers to discontinuation from treatment. Results are reported as number of patients with TEAEs for each of the indicated categories.

Time frame:
168 days (up to Cycle 6 Day 28 in Part B).
Reported as:
Number · participants
Number of Patients Experiencing TEAEs After 6 Cycles in Part B of the Study
participantsGivinostat at MTD (100 mg b.i.d.) (Part B)
TEAE35
Drug-related TEAE33
TESAE2
Drug-related TESAE1
Death due to any cause0
Grade 3 TEAE12
Grade 3 drug-related TEAE10
Grade 4 TEAE0
Grade 4 drug-related TEAE0
Grade 5 TEAE0
Discontinuation due to TEAE2
Discontinuation due to drug-related TEAE2
Discontinuation due to TESAE0
Discontinuation due to drug-related TESAE0
SecondaryAssessment of Maximum Plasma Concentration (Cmax) of Givinostat and Metabolites (ITF2374 and ITF2375) in Part A of the Study

Pharmacokinetic (PK) evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Cmax following administration of givinostat for 1 cycle in Part A. PK calculations were performed by standard non-compartmental analysis. Results are reported for Cycle 1 Day 1 and Cycle 1 Day 28. Note: concentration data for ITF2374 (Cycle 1 Day 1 and Cycle 1 Day 28) and for ITF2375 (Cycle 1 Day 1) in the DL0 dose group of Part A were not available for PK analysis.

Time frame:
Blood samples were collected in Part A on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 1 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.
Reported as:
Mean · nanograms per millilitre (ng/mL)
Assessment of Maximum Plasma Concentration (Cmax) of Givinostat and Metabolites (ITF2374 and ITF2375) in Part A of the Study
nanograms per millilitre (ng/mL)Givinostat DL0 (50 mg b.i.d.) (Part A PK Analysis Set)Givinostat DL1 (100 mg b.i.d.) (Part A PK Analysis Set)Givinostat DL6 (100 mg + 50 mg) (Part A PK Analysis Set)
Givinostat Cycle 1 Day 160.2 ± 43.154.3 ± 17.282.5 ± 24.4
ITF2374 Cycle 1 Day 1—3.74 ± 4.095.69 ± 2.87
ITF2375 Cycle 1 Day 1—68.6 ± 21.2101 ± 24.5
Givinostat Cycle 1 Day 2822.4 ± 8.9273.3 ± 31.9290 ± 330
ITF2374 Cycle 1 Day 28—19.7 ± 7.2431.3 ± 4.95
ITF2375 Cycle 1 Day 28110 ± 22.8259 ± 75.9376 ± 215
SecondaryAssessment of Time to Maximum Plasma Concentration (Tmax) of Givinostat and Metabolites (ITF2374 and ITF2375) in Part A of the Study

PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Tmax following administration of givinostat for 1 cycle in Part A. PK calculations were performed by standard non-compartmental analysis. Results are reported for Cycle 1 Day 1 and Cycle 1 Day 28. Note: concentration data for ITF2374 (Cycle 1 Day 1 and Cycle 1 Day 28) and for ITF2375 (Cycle 1 Day 1) in the DL0 dose group of Part A were not available for PK analysis.

Time frame:
Blood samples were collected in Part A on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 1 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.
Reported as:
Median · hours
Assessment of Time to Maximum Plasma Concentration (Tmax) of Givinostat and Metabolites (ITF2374 and ITF2375) in Part A of the Study
hoursGivinostat DL0 (50 mg b.i.d.) (Part A PK Analysis Set)Givinostat DL1 (100 mg b.i.d.) (Part A PK Analysis Set)Givinostat DL6 (100 mg + 50 mg) (Part A PK Analysis Set)
Givinostat Cycle 1 Day 12.00 (1.92 to 3.00)2.00 (2.00 to 2.00)3.00 (2.00 to 3.00)
ITF2374 Cycle 1 Day 1—8.00 (8.00 to 8.00)8.00 (3.00 to 8.00)
ITF2375 Cycle 1 Day 1—3.00 (2.00 to 3.00)2.50 (2.00 to 3.00)
Givinostat Cycle 1 Day 283.90 (3.83 to 4.00)1.50 (1.00 to 3.98)2.05 (1.05 to 4.00)
ITF2374 Cycle 1 Day 28—8.00 (0.00 to 8.00)2.00 (1.05 to 4.05)
ITF2375 Cycle 1 Day 282.00 (2.00 to 2.00)1.99 (1.00 to 3.98)4.00 (0.00 to 4.05)
SecondaryAssessment of Time of the Last Detectable Concentration (Tlast) of Givinostat and Metabolites (ITF2374 and ITF2375) in Part A of the Study

PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Tlast following administration of givinostat for 1 cycle in Part A. PK calculations were performed by standard non-compartmental analysis. Results are reported for Cycle 1 Day 1 and Cycle 1 Day 28. Note: concentration data for ITF2374 (Cycle 1 Day 1 and Cycle 1 Day 28) and for ITF2375 (Cycle 1 Day 1) in the DL0 dose group of Part A were not available for PK analysis.

Time frame:
Blood samples were collected in Part A on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 1 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.
Reported as:
Mean · hours
Assessment of Time of the Last Detectable Concentration (Tlast) of Givinostat and Metabolites (ITF2374 and ITF2375) in Part A of the Study
hoursGivinostat DL0 (50 mg b.i.d.) (Part A PK Analysis Set)Givinostat DL1 (100 mg b.i.d.) (Part A PK Analysis Set)Givinostat DL6 (100 mg + 50 mg) (Part A PK Analysis Set)
Givinostat Cycle 1 Day 17.97 ± 0.04628.00 ± 0.008.00 ± 0.00
ITF2374 Cycle 1 Day 1—8.00 ± 0.008.00 ± 0.00
ITF2375 Cycle 1 Day 1—8.00 ± 0.008.00 ± 0.00
Givinostat Cycle 1 Day 288.05 ± 0.2497.00 ± 2.018.02 ± 0.0252
ITF2374 Cycle 1 Day 28—7.00 ± 2.018.02 ± 0.0252
ITF2375 Cycle 1 Day 283.00 ± 1.417.00 ± 2.016.70 ± 2.30
SecondaryAssessment of Area Under Plasma Concentration Versus the Time Curve up to the Last Detectable Concentration (AUClast) of Givinostat and Metabolites (ITF2374 and ITF2375) in Part A of the Study

PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of AUClast following administration of givinostat for 1 cycle in Part A. PK calculations were performed by standard non-compartmental analysis and AUClast was calculated using the linear trapezoidal rule. Results are reported for Cycle 1 Day 1 and Cycle 1 Day 28. Note: concentration data for ITF2374 (Cycle 1 Day 1 and Cycle 1 Day 28) and for ITF2375 (Cycle 1 Day 1) in the DL0 dose group of Part A were not available for PK analysis.

Time frame:
Blood samples were collected in Part A on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 1 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.
Reported as:
Mean · ng*h/mL
Assessment of Area Under Plasma Concentration Versus the Time Curve up to the Last Detectable Concentration (AUClast) of Givinostat and Metabolites (ITF2374 and ITF2375) in Part A of the Study
ng*h/mLGivinostat DL0 (50 mg b.i.d.) (Part A PK Analysis Set)Givinostat DL1 (100 mg b.i.d.) (Part A PK Analysis Set)Givinostat DL6 (100 mg + 50 mg) (Part A PK Analysis Set)
Givinostat Cycle 1 Day 1208 ± 136238 ± 55.6429 ± 109
ITF2374 Cycle 1 Day 1—14.4 ± 19.029.6 ± 9.64
ITF2375 Cycle 1 Day 1—416 ± 153611 ± 146
Givinostat Cycle 1 Day 28132 ± 45.1359 ± 2031100 ± 1050
ITF2374 Cycle 1 Day 28—102 ± 11.7158 ± 42.6
ITF2375 Cycle 1 Day 28263 ± 1921390 ± 6751780 ± 1190
SecondaryAssessment of Area Under Plasma Concentration Versus the Time Curve in the Dosing Interval (0-12 Hours) (AUC0-12) of Givinostat and Metabolites (ITF2374 and ITF2375) in Part A of the Study

PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of AUC0-12 following administration of givinostat for 1 cycle in Part A. PK calculations were performed by standard non-compartmental analysis and AUC0-12 was calculated using the linear trapezoidal rule. Results are reported for Cycle 1 Day 1 and Cycle 1 Day 28. Note:concentration data for ITF2374 (Cycle 1 Day 1 and Cycle 1 Day 28) across all dose groups and for ITF2375 (Cycle 1 Day 1) in the DL0 dose group of Part A were not available for PK analysis.

Time frame:
Blood samples were collected in Part A on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 1 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.
Reported as:
Mean · ng*h/mL
Assessment of Area Under Plasma Concentration Versus the Time Curve in the Dosing Interval (0-12 Hours) (AUC0-12) of Givinostat and Metabolites (ITF2374 and ITF2375) in Part A of the Study
ng*h/mLGivinostat DL0 (50 mg b.i.d.) (Part A PK Analysis Set)Givinostat DL1 (100 mg b.i.d.) (Part A PK Analysis Set)Givinostat DL6 (100 mg + 50 mg) (Part A PK Analysis Set)
Givinostat Cycle 1 Day 1235 ± 146289 ± 68.9508 ± 107
ITF2375 Cycle 1 Day 1—598 ± 259870 ± 182
Givinostat Cycle 1 Day 28161 ± 51.8533 ± 2231180 ± 1050
ITF2375 Cycle 1 Day 28863 ± NA2020 ± 10002340 ± 970
SecondaryAssessment of Cmax of Givinostat and Metabolites (ITF2374 and ITF2375) in Part B of the Study

PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Cmax following administration of givinostat for 2 cycles in Part B. PK calculations were performed by standard non-compartmental analysis. Following definition of the MTD in Part A, during Part B Cycle 1, givinostat was administered at 100 mg b.i.d. and during Part B Cycle 2 was administered at 100 mg, 75 mg and 50 mg b.i.d. (since dose reductions due to TEAEs were allowed from Cycle 2 onwards, as per protocol). Results are reported for Cycle 1 Day 1 and Cycle 2 Day 28 for the doses administered during Part B. Note: PK evaluation for the givinostat 75 mg and 50 mg b.i.d. dose groups for Cycle 1 Day 1 was not applicable (since all received givinostat 100 mg b.i.d.). Additionally, concentration data for ITF2375 (Cycle 1 Day 28) in the 50 mg b.i.d. dose group was not available for PK analysis.

Time frame:
Blood samples were collected in Part B on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 2 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.
Reported as:
Mean · ng/mL
Assessment of Cmax of Givinostat and Metabolites (ITF2374 and ITF2375) in Part B of the Study
ng/mLGivinostat 100 mg b.i.d. (Part B PK Analysis Set)Givinostat 75 mg b.i.d. (Part B PK Analysis Set)Givinostat 50 mg b.i.d. (Part B PK Analysis Set)
Givinostat Cycle 1 Day 171.5 ± 34.4——
ITF2374 Cycle 1 Day 17.85 ± 4.89——
ITF2375 Cycle 1 Day 1161 ± 72.9——
Givinostat Cycle 2 Day 2890.8 ± 33.564.0 ± 22.662.6 ± 21.8
ITF2374 Cycle 2 Day 2832.3 ± 21.022.6 ± 11.221.4 ± 0.424
ITF2375 Cycle 2 Day 28320 ± 238203 ± 78.7—
SecondaryAssessment of Tmax of Givinostat and Metabolites (ITF2374 and ITF2375) in Part B of the Study

PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Tmax following administration of givinostat for 2 cycles in Part B. PK calculations were performed by standard non-compartmental analysis. Following definition of the MTD in Part A, during Part B Cycle 1, givinostat was administered at 100 mg b.i.d. and during Part B Cycle 2 was administered at 100 mg, 75 mg and 50 mg b.i.d. (since dose reductions due to TEAEs were allowed from Cycle 2 onwards, as per protocol). Results are reported for Cycle 1 Day 1 and Cycle 2 Day 28 for the doses administered during Part B. Note: PK evaluation for the givinostat 75 mg and 50 mg b.i.d. dose groups for Cycle 1 Day 1 was not applicable (since all received givinostat 100 mg b.i.d.). Additionally, concentration data for ITF2375 (Cycle 1 Day 28) in the 50 mg b.i.d. dose group was not available for PK analysis.

Time frame:
Blood samples were collected in Part B on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 2 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.
Reported as:
Median · hours
Assessment of Tmax of Givinostat and Metabolites (ITF2374 and ITF2375) in Part B of the Study
hoursGivinostat 100 mg b.i.d. (Part B PK Analysis Set)Givinostat 75 mg b.i.d. (Part B PK Analysis Set)Givinostat 50 mg b.i.d. (Part B PK Analysis Set)
Givinostat Cycle 1 Day 12.00 (0.00 to 8.00)——
ITF2374 Cycle 1 Day 18.00 (2.08 to 8.17)——
ITF2375 Cycle 1 Day 13.00 (1.83 to 8.00)——
Givinostat Cycle 2 Day 282.00 (0.00 to 4.07)2.00 (1.00 to 8.00)0.985 (0.00 to 1.97)
ITF2374 Cycle 2 Day 284.00 (0.00 to 8.00)3.04 (1.00 to 8.00)5.99 (3.97 to 8.00)
ITF2375 Cycle 2 Day 282.00 (0.00 to 4.00)2.00 (1.00 to 8.00)—
SecondaryAssessment of Tlast of Givinostat and Metabolites (ITF2374 and ITF2375) in Part B of the Study

PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Tlast following administration of givinostat for 2 cycles in Part B. PK calculations were performed by standard non-compartmental analysis. Following definition of the MTD in Part A, during Part B Cycle 1, givinostat was administered at 100 mg b.i.d. and during Part B Cycle 2 was administered at 100 mg, 75 mg and 50 mg b.i.d. (since dose reductions due to TEAEs were allowed from Cycle 2 onwards, as per protocol). Results are reported for Cycle 1 Day 1 and Cycle 2 Day 28 for the doses administered during Part B. Note: PK evaluation for the givinostat 75 mg and 50 mg b.i.d. dose groups for Cycle 1 Day 1 was not applicable (since all received givinostat 100 mg b.i.d.). Additionally, concentration data for ITF2375 (Cycle 1 Day 28) in the 50 mg b.i.d. dose group was not available for PK analysis.

Time frame:
Blood samples were collected in Part B on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 2 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.
Reported as:
Mean · hours
Assessment of Tlast of Givinostat and Metabolites (ITF2374 and ITF2375) in Part B of the Study
hoursGivinostat 100 mg b.i.d. (Part B PK Analysis Set)Givinostat 75 mg b.i.d. (Part B PK Analysis Set)Givinostat 50 mg b.i.d. (Part B PK Analysis Set)
Givinostat Cycle 1 Day 17.42 ± 1.61——
ITF2374 Cycle 1 Day 17.42 ± 1.61——
ITF2375 Cycle 1 Day 18.00 ± 0.0505——
Givinostat Cycle 2 Day 288.00 ± 0.03407.98 ± 0.07537.99 ± 0.0212
ITF2374 Cycle 2 Day 288.00 ± 0.03407.98 ± 0.07537.99 ± 0.0212
ITF2375 Cycle 2 Day 287.75 ± 1.008.00 ± 0.00—
SecondaryAssessment of AUClast of Givinostat and Metabolites (ITF2374 and ITF2375) in Part B of the Study

PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of AUClast following administration of givinostat for 2 cycles in Part B. PK calculations were performed by standard non-compartmental analysis and AUClast was calculated using the linear trapezoidal rule. Following definition of the MTD in Part A, during Part B Cycle 1, givinostat was administered at 100 mg b.i.d. and during Part B Cycle 2 was administered at 100 mg, 75 mg and 50 mg b.i.d. (since dose reductions due to TEAEs were allowed from Cycle 2 onwards, as per protocol). Results are reported for Cycle 1 Day 1 and Cycle 2 Day 28 for the for the doses administered during Part B. Note: PK evaluation for the givinostat 75 mg and 50 mg b.i.d. dose groups for Cycle 1 Day 1 was not applicable (since all received givinostat 100 mg b.i.d.). Additionally, concentration data for ITF2375 (Cycle 1 Day 28) in the 50 mg b.i.d. dose group was not available for PK analysis.

Time frame:
Blood samples were collected in Part B on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 2 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.
Reported as:
Mean · ng*h/mL
Assessment of AUClast of Givinostat and Metabolites (ITF2374 and ITF2375) in Part B of the Study
ng*h/mLGivinostat 100 mg b.i.d. (Part B PK Analysis Set)Givinostat 75 mg b.i.d. (Part B PK Analysis Set)Givinostat 50 mg b.i.d. (Part B PK Analysis Set)
Givinostat Cycle 1 Day 1289 ± 130——
ITF2374 Cycle 1 Day 128.5 ± 14.0——
ITF2375 Cycle 1 Day 1888 ± 439——
Givinostat Cycle 2 Day 28459 ± 145323 ± 107269 ± 78.5
ITF2374 Cycle 2 Day 28216 ± 127161 ± 83.5145 ± 20.9
ITF2375 Cycle 2 Day 281830 ± 16601210 ± 585—
SecondaryAssessment of AUC0-12 of Givinostat and Metabolites (ITF2374 and ITF2375) in Part B of the Study

PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of AUC0-12 following administration of givinostat for 2 cycles in Part B. PK calculations were performed by standard non-compartmental analysis and AUClast was calculated using the linear trapezoidal rule. Following definition of the MTD in Part A, during Part B Cycle 1, givinostat was administered at 100 mg b.i.d. and during Part B Cycle 2 was administered at 100 mg, 75 mg and 50 mg b.i.d. (since dose reductions due to TEAEs were allowed from Cycle 2 onwards, as per protocol). Results are reported for Cycle 1 Day 1 and Cycle 2 Day 28 for the doses administered during Part B. Note: PK evaluation for the givinostat 75 mg and 50 mg b.i.d. dose groups for Cycle 1 Day 1 was not applicable (since all received givinostat 100 mg b.i.d.). Additionally, concentration data for ITF2374 (Cycle 1 Day 28) across all dose groups and for ITF2375 in the 50 mg b.i.d. dose group was not available for PK analysis.

Time frame:
Blood samples were collected in Part B on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 2 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose.
Reported as:
Mean · ng*h/mL
Assessment of AUC0-12 of Givinostat and Metabolites (ITF2374 and ITF2375) in Part B of the Study
ng*h/mLGivinostat 100 mg b.i.d. (Part B PK Analysis Set)Givinostat 75 mg b.i.d. (Part B PK Analysis Set)Givinostat 50 mg b.i.d. (Part B PK Analysis Set)
Givinostat Cycle 1 Day 1372 ± 137——
ITF2375 Cycle 1 Day 11080 ± 619——
Givinostat Cycle 2 Day 28561 ± 176410 ± 129326 ± 54.0
ITF2375 Cycle 2 Day 282460 ± 24501460 ± 608—

Adverse events

Collected over 168 days for Part A and 168 days for Part B (Cycle 1 through Cycle 6 for each phase of study; each cycle 28 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Givinostat DL0 (50 mg b.i.d.) (Part A)0/3 (0%)0/3 (0%)3/3 (100%)
Givinostat DL1 (100 mg b.i.d.) (Part A)0/3 (0%)1/3 (33.3%)3/3 (100%)
Givinostat DL1 Expanded (100 mg b.i.d.) (Part A)0/3 (0%)0/3 (0%)3/3 (100%)
Givinostat DL6 (100 mg + 50 mg) (Part A)0/3 (0%)1/3 (33.3%)3/3 (100%)
Givinostat at MTD (100 mg b.i.d.) (Part B)0/35 (0%)2/35 (5.7%)35/35 (100%)
Most frequent serious events
Most frequent serious events
EventGivinostat DL0 (50 mg b.i.d.) (Part A)Givinostat DL1 (100 mg b.i.d.) (Part A)Givinostat DL1 Expanded (100 mg b.i.d.) (Part A)Givinostat DL6 (100 mg + 50 mg) (Part A)Givinostat at MTD (100 mg b.i.d.) (Part B)
Myocardial infarctionCardiac disorders0/30/30/31/30/35
ThrombophlebitisVascular disorders0/31/30/30/30/35
DiarrhoeaGastrointestinal disorders0/30/30/30/31/35
PneumoniaInfections and infestations0/30/30/30/31/35
Most frequent other events
Showing 10 of 65
Most frequent other events
EventGivinostat DL0 (50 mg b.i.d.) (Part A)Givinostat DL1 (100 mg b.i.d.) (Part A)Givinostat DL1 Expanded (100 mg b.i.d.) (Part A)Givinostat DL6 (100 mg + 50 mg) (Part A)Givinostat at MTD (100 mg b.i.d.) (Part B)
ThrombocytopeniaBlood and lymphatic system disorders0/32/32/30/316/35
DiarrhoeaGastrointestinal disorders1/32/32/32/320/35
DyspepsiaGastrointestinal disorders1/32/30/30/35/35
DysgeusiaNervous system disorders0/31/31/32/33/35
Oropharyngeal painRespiratory, thoracic and mediastinal disorders2/30/30/30/31/35
Blood creatinine increasedInvestigations0/30/30/31/314/35
Haemolytic anaemiaBlood and lymphatic system disorders0/30/31/30/30/35
PalpitationsCardiac disorders0/31/30/30/33/35
HypothyroidismEndocrine disorders1/30/30/30/30/35
Abdominal painGastrointestinal disorders0/30/30/31/38/35

Baseline characteristics

The overall baseline population consists of all enrolled patients in either Part A or Part B of the study.

Age, Categorical
Age, Categorical(Participants)Givinostat DL0 (50 mg b.i.d.) (Part A)Givinostat DL1 (100 mg b.i.d.) (Part A)Givinostat DL1 Expanded (100 mg b.i.d.) (Part A)Givinostat DL6 (100 mg + 50 mg) (Part A)Givinostat at MTD (100 mg b.i.d.) (Part B)Total Title
<=18 years000000
Between 18 and 65 years22122835
>=65 years1121813
Sex: Female, Male
Sex: Female, Male(Participants)Givinostat DL0 (50 mg b.i.d.) (Part A)Givinostat DL1 (100 mg b.i.d.) (Part A)Givinostat DL1 Expanded (100 mg b.i.d.) (Part A)Givinostat DL6 (100 mg + 50 mg) (Part A)Givinostat at MTD (100 mg b.i.d.) (Part B)Total Title
Female21111116
Male12222532
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Givinostat DL0 (50 mg b.i.d.) (Part A)Givinostat DL1 (100 mg b.i.d.) (Part A)Givinostat DL1 Expanded (100 mg b.i.d.) (Part A)Givinostat DL6 (100 mg + 50 mg) (Part A)Givinostat at MTD (100 mg b.i.d.) (Part B)Total Title
American Indian or Alaska Native000000
Asian000000
Native Hawaiian or Other Pacific Islander000000
Black or African American000000
White33333648
More than one race000000
Unknown or Not Reported000000
08

Study locations

25 sites
  • CHU Amiens - Hôpital Sud
    Amiens Cedex 1, 80054, France
  • Hôpital Morvan - CHRU de Brest
    Brest Cedex, 29609, France
  • Hopital Saint Vincent de Paul - GHICL Lille
    Lille cedex, 59020, France
  • Hôpital Saint-Louis (AP-HP), Centre Investigations Cliniques
    Paris Cedex 10, 75475, France
  • Charite Research Organisation GmbH
    Berlin, 10117, Germany
  • Universitaetsklinikum Carl Gustav Carus TU Dresden
    Dresden, 01307, Germany
  • Universitaetsklinikum Freiburg
    Freiburg, 79106, Germany
  • Universitaetsklinikum Koeln
    Koeln, 50937, Germany
  • Azienda ospedaliero universitaria Consorziale Policlinico di Bari
    Bari, BA 70124, Italy
  • Azienda Ospedaliera Papa Giovanni XXIII
    Bergamo, BG 24127, Italy
  • Azienda Ospedaliero-Universitaria Careggi, Florence
    Florence, FI 50134, Italy
  • Fondazione IRCCS Policlinico San Matteo
    Pavia, PV 27100, Italy
  • Istituto Tumori Giovanni Paolo II - IRCCS Ospedale Oncologico di Bari
    Bari, 70124, Italy
  • Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico
    Milano, Italy
  • Università degli Studi di Napoli Federico II, Facoltà di Medicina e Chirurgia
    Napoli, 80131, Italy
  • Ospedale Civile dello Spirito Santo
    Pescara, Italy
  • Azienda Ospedaliero Universitaria Pisana
    Pisa, 56126, Italy
  • Azienda Ospedaliera "Bianchi-Melacrino-Morelli"
    Reggio Calabria, 89125, Italy
  • Università Campus Bio-Medico di Roma
    Rome, Italy
  • Ospedale San Bortolo di Vicenza
    Vicenza, 36100, Italy
  • SP ZOZ Zespol Szpitali Miejskich w Chorzowie
    Chorzow, 41-500, Poland
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, 80-952, Poland
  • Belfast City Hospital
    Belfast, BT9 7BL, United Kingdom
  • Royal London Hospital
    London, E1 1BB, United Kingdom
  • Royal Cornwall Hospital
    Truro, TR1 3LJ, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of Jun 2017 and a completion of Sep 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2019, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2013
First posted
Jul 17, 2013
Start
Oct 2013
Primary completionActual
Jun 26, 2017
CompletionActual
Sep 25, 2017
Results first posted
Jun 20, 2019
Last update
Jul 30, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01901432
Lead sponsor
Italfarmaco
Responsible party
Sponsor
First posted
Jul 17, 2013
Start date
Oct 2013
Primary completion
Jun 26, 2017
Completion
Sep 25, 2017
Results posted
Jun 20, 2019
Last update
Jul 30, 2019

Study contacts

Paolo Bettica, MD
study director · Italfarmaco S.p.A.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Givinostat

Start the discussion